Search
Bicycle Therapeutics PLC
BCYCAdd to Watchlist
4.350USD
+0.140+3.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
217.20MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.33%
5 Days
+6.10%
1 Month
+1.87%
6 Months
-34.88%
Year to Date
-38.56%
1 Year
-41.45%
Key Figures
4.220Open
4.395High
353.69KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.71%Turnover Ratio
4.210Prev. Close
4.210Low
991.28KTurnover
LossP/E Static
0.36P/B
0.00%Div Yield TTM
-28.51%ROA
9.36052wk High
1.09Volume Ratio
-169.03MNet Profit
49.93MShares
-3.1554EPS TTM
1.55Beta
-33.84%ROE
4.24052wk Low
4.39%Amplitude
100.00%Gross Margin
217.20MMarket Cap
-0.46Reward/Risk
3.07%Risk Rate
TradingKey Stock Score of Bicycle Therapeutics PLC
Currency: USD Updated: 2026-07-02Key Insights
Bicycle Therapeutics PLC's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 152 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.78.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bicycle Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Bicycle Therapeutics PLC Highlights
StrengthsRisks
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 169.08% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 72.59M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 72.59M.
Overvalued
The company’s latest PE is -1.38, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 33.87M shares, decreasing 40.59% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 280.09K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
12.778
Target Price
+203.51%
Upside Space
Bicycle Therapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bicycle Therapeutics PLC Info
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Ticker SymbolBCYC
CompanyBicycle Therapeutics PLC
CEOLee (Kevin)
Websitehttps://www.bicycletherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Bicycle Therapeutics PLC (BCYC)?
The current price of Bicycle Therapeutics PLC (BCYC) is 4.35.
What is the symbol of Bicycle Therapeutics PLC?
The ticker symbol of Bicycle Therapeutics PLC is BCYC.
What is the 52-week high of Bicycle Therapeutics PLC?
The 52-week high of Bicycle Therapeutics PLC is 9.36.
What is the 52-week low of Bicycle Therapeutics PLC?
The 52-week low of Bicycle Therapeutics PLC is 4.24.
What is the market capitalization of Bicycle Therapeutics PLC?
The market capitalization of Bicycle Therapeutics PLC is 217.20M.
Is Bicycle Therapeutics PLC (BCYC) currently rated as Buy, Hold, or Sell?
According to analysts, Bicycle Therapeutics PLC (BCYC) has an overall rating of Buy, with a price target of 12.78.
What is the Earnings Per Share (EPS TTM) of Bicycle Therapeutics PLC (BCYC)?
The Earnings Per Share (EPS TTM) of Bicycle Therapeutics PLC (BCYC) is -3.16.